NASDAQ:KNSA Kiniksa Pharmaceuticals International (KNSA) Stock Price, News & Analysis $52.86 -0.38 (-0.71%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kiniksa Pharmaceuticals International Stock (NASDAQ:KNSA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get KNSA alerts:Sign Up Key Stats Today's Range$52.26▼$53.6350-Day Range$42.45▼$59.4852-Week Range$26.27▼$59.87Volume551,346 shsAverage Volume708,587 shsMarket Capitalization$4.07 billionP/E Ratio58.73Dividend YieldN/APrice Target$60.86Consensus RatingModerate Buy Company Overview Kiniksa Pharmaceuticals International, Inc. is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies. The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome. Beyond Ilaris, Kiniksa’s clinical pipeline includes mavrilimumab, a monoclonal antibody targeting the GM-CSF receptor being investigated for giant cell arteritis; remibrutinib, a selective BTK inhibitor in Phase III studies for chronic spontaneous urticaria; and pozelimab, an anti-C5 monoclonal antibody under development for rare complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria and myasthenia gravis. Kiniksa operates globally, with commercial and development activities spanning North America, Europe and Asia under various licensing and distribution arrangements. The company is led by Founder and Chief Executive Officer John H. Johnson, who oversees a management team composed of experienced biopharmaceutical executives and scientific leaders. By combining strategic partnerships, disciplined capital allocation and a targeted R&D strategy, Kiniksa aims to deliver therapies that can transform the treatment landscape for patients with serious immune diseases.AI Generated. May Contain Errors. Read More Kiniksa Pharmaceuticals International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreKNSA MarketRank™: Kiniksa Pharmaceuticals International scored higher than 87% of companies evaluated by MarketBeat, and ranked 80th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingKiniksa Pharmaceuticals International has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialKiniksa Pharmaceuticals International has a consensus price target of $60.86, representing about 15.1% upside from its current price of $52.86.Amount of Analyst CoverageKiniksa Pharmaceuticals International has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kiniksa Pharmaceuticals International's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth37.10% Earnings GrowthEarnings for Kiniksa Pharmaceuticals International are expected to grow by 37.10% in the coming year, from $1.24 to $1.70 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiniksa Pharmaceuticals International is 58.73, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiniksa Pharmaceuticals International is 58.73, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.88.Price to Book Value per Share RatioKiniksa Pharmaceuticals International has a P/B Ratio of 6.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kiniksa Pharmaceuticals International's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.86% of the float of Kiniksa Pharmaceuticals International has been sold short.Short Interest Ratio / Days to CoverKiniksa Pharmaceuticals International has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiniksa Pharmaceuticals International has recently decreased by 13.78%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKiniksa Pharmaceuticals International does not currently pay a dividend.Dividend GrowthKiniksa Pharmaceuticals International does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.25 News SentimentKiniksa Pharmaceuticals International has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Kiniksa Pharmaceuticals International this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for KNSA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows6 people have added Kiniksa Pharmaceuticals International to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Kiniksa Pharmaceuticals International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,046,073.00 in company stock.Percentage Held by Insiders51.98% of the stock of Kiniksa Pharmaceuticals International is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.95% of the stock of Kiniksa Pharmaceuticals International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiniksa Pharmaceuticals International's insider trading history. Receive KNSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KNSA Stock News HeadlinesKiniksa Pharmaceuticals Caps Major Shareholder Voting Control Rights2 hours ago | tipranks.comKiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of "Moderate Buy" by BrokeragesMay 23 at 2:47 AM | americanbankingnews.comJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.May 26 at 1:00 AM | Brownstone Research (Ad)Kiniksa Pharmaceuticals Still Has Room to Run After 100% RallyKiniksa Pharmaceuticals is gaining momentum after strong ARCALYST sales growth, raised revenue guidance, and optimism surrounding its next-generation pipeline...May 22, 2026 | marketbeat.comKiniksa Pharmaceuticals International (KNSA) price target increased by 10.10% to 63.53May 14, 2026 | msn.comInsider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider Sells $3,137,953.04 in StockMay 6, 2026 | insidertrades.comInsider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells 48,565 Shares of StockMay 2, 2026 | insidertrades.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $115,635.41 in StockMay 1, 2026 | insidertrades.comSee More Headlines KNSA Stock Analysis - Frequently Asked Questions How have KNSA shares performed this year? Kiniksa Pharmaceuticals International's stock was trading at $41.25 at the beginning of 2026. Since then, KNSA shares have increased by 28.1% and is now trading at $52.86. How were Kiniksa Pharmaceuticals International's earnings last quarter? Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) issued its quarterly earnings results on Tuesday, April, 28th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International's revenue for the quarter was up 55.5% compared to the same quarter last year. Read the conference call transcript. When did Kiniksa Pharmaceuticals International IPO? Kiniksa Pharmaceuticals International (KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Kiniksa Pharmaceuticals International's major shareholders? Kiniksa Pharmaceuticals International's top institutional investors include Rubric Capital Management LP (4.87%), Arrowstreet Capital Limited Partnership (1.16%), Dimensional Fund Advisors LP (1.06%) and Spruce Street Capital LP (0.99%). Insiders that own company stock include John F Paolini, Sanj K Patel, Michael R Megna, Eben Tessari, Thomas Malley, Barry D Quart, Mark Ragosa and Ross Moat. View institutional ownership trends. How do I buy shares of Kiniksa Pharmaceuticals International? Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kiniksa Pharmaceuticals International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiniksa Pharmaceuticals International investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings4/28/2026Today5/26/2026Next Earnings (Estimated)7/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 KNSA's financial health is in the Green zone, according to TradeSmith. KNSA has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KNSA CIK1730430 Webwww.kiniksa.com Phone(781) 431-9100FaxN/AEmployees220Year Founded2015Price Target and Rating Average Price Target for Kiniksa Pharmaceuticals International$60.86 High Price Target$71.00 Low Price Target$55.00 Potential Upside/Downside+15.1%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$0.90 Trailing P/E Ratio58.73 Forward P/E Ratio42.63 P/E GrowthN/ANet Income$59.01 million Net Margins9.69% Pretax Margin14.06% Return on Equity13.26% Return on Assets9.86% Debt Debt-to-Equity RatioN/A Current Ratio3.79 Quick Ratio3.33 Sales & Book Value Annual Sales$677.56 million Price / Sales6.00 Cash Flow$0.79 per share Price / Cash Flow67.07 Book Value$7.87 per share Price / Book6.72Miscellaneous Outstanding Shares76,940,000Free Float36,946,000Market Cap$4.07 billion OptionableOptionable Beta0.17 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:KNSA) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredElon Confirms SpaceX IPO For 6/12 [Act Now!]Elon Musk has confirmed SpaceX will IPO on Friday, June 12, 2026, at a valuation of up to $2 trillion - potent...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals International, plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
